ArticlePloS one2019
Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The Potential of Selective COX-2 Inhibitor Mavacoxib for Extended Analgesia in Sheep Husbandry.Animals : an open access journal from MDPI · 2026Article
- Article
- Pharmacokinetics and preliminary data on safety of meloxicam subcutaneous extended-release formulation in Sprague-Dawley rats.Frontiers in veterinary science · 2026Article
- Analgesic combinations to reduce the stress/pain responses in ewes submitted to non-surgical embryo recovery: butorphanol associated with meloxicam or with dipyrone/hyoscine.Animal reproduction · 2026Article
- Comparing Pharmacokinetics of Meloxicam When Administered With a Needle-Free Injection Device Versus Needle-And-Syringe in Piglets.Journal of veterinary pharmacology and therapeutics · 2026Article
- Effect of Gender on the Pharmacokinetics of Meloxicam in Sheep.Journal of veterinary pharmacology and therapeutics · 2025Article
- Effect of Meloxicam on the Pharmacokinetics of Cefquinome in Endotoxemic Sheep.Veterinary medicine and science · 2025Article
- Comparison of Intravenous and Oral Meloxicam Pharmacokinetics in Female and Male Saanen Goats.Veterinary sciences · 2025Article
- Neuroinflammatory crosstalk in migraine: consolidated activity of rizatriptan and meloxicam in suppressing CGRP-induced nociception and COX-mediated inflammation.Inflammopharmacology · 2025Review
- Medicated Meloxicam Pellets Reduce Some Indicators of Pain in Disbudded Dairy Calves.Animals : an open access journal from MDPI · 2025Article
- The effect of a non-steroidal anti-inflammatory drug on the locomotor activity of reindeer (Rangifer tarandus tarandus) on their natural pastures after clamp castration-a pilot study.Acta veterinaria Scandinavica · 2025Article
- Self-Administration of Meloxicam via Medicated Molasses Lick Blocks May Improve Welfare of Castrated Calves.Animals : an open access journal from MDPI · 2025Article
- Pharmacokinetics of Meloxicam in Different Animal Species: A Comprehensive Review.Veterinary sciences · 2024Review
- Article
- Standing sedation management of a domesticated reindeer for third eyelid removal.Open veterinary journal · 2023Article
- Pharmacokinetic Parameters and Tissue Withdrawal Intervals for Sheep Administered Multiple Oral Doses of Meloxicam.Animals : an open access journal from MDPI · 2021Article
- Preliminary Investigation into a Novel Sustained-Release Formulation of Meloxicam in Sheep (Animals : an open access journal from MDPI · 2021Article
- Analgesia for Sheep in Commercial Production: Where to Next?Animals : an open access journal from MDPI · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma pharmacokinetic profiles and the anti-inflammatory efficacy of meloxicam were determined when administered subcutaneously (SC) or intramuscularly (IM) to sheep. Merino ewes were initially injected with 0.1 mL of oil of turpentine into a forelimb to induce inflammation, followed by either 1.0 mg/kg or 2.0 mg/kg of meloxicam administered either SC or IM (n = 6 per treatment group) or followed by no meloxicam administration (control) (n = 4). Ewes were examined to determine skin temperature, limb circumference, limb sensitivity and signs of lameness at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 48 h following treatment, with blood collected at these time-points to quantify meloxicam plasma concentrations. Skin temperature of ewes dosed with meloxicam at 1.0 mg/kg SC and 2.0 mg/kg IM at 12 h and 1.0 mg/kg SC at 24 were significantly different to the controls (P < 0.05). Limb circumferences of ewes dosed with 1.0 mg/kg IM were significantly different to controls at 10 h and 12 h (P < 0.05). All meloxicam treatment groups resulted in reduced limb sensitivity compared to controls at 6 h, with the 1.0 and 2.0 mg/kg IM treatments significantly different at 12 h (P < 0.05) and 1.0 and 2.0 mg/kg SC groups, significantly different to controls at 48 h (P < 0.05). No significant difference in lameness scores were detected over 48 h. The 1.0 mg/kg IM treatment had a significantly greater plasma meloxicam concentration than the 1.0 mg/kg SC treatment over 0.5 to 4 h (P < 0.001). Both 1.0 mg/kg SC and IM treatments demonstrated elimination half-lives (mean ± SD) of 10.82 ± 2.46 and 12.63 ± 2.37 h, respectively. Meloxicam at all doses provided some anti-inflammatory and analgesic effects from 6 to 48 h; however no route could be distinguished as more efficacious than the others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.